不明原因胆汁淤积诊断思路

doi:10.3969/j.issn.1672-5069.2018.01.005

Abstract

Xiong Qingfang, Yang Yongfeng. Diagnosis of patients with unknown cause cholestasis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 18-20.

[1] 中华医学会肝病学分会、消化病学分会、感染病学分会. 胆汁淤积性肝病诊断和治疗共识（2015）. 实用肝脏病杂志,2016,19（6）：Ⅰ-Ⅺ.
[2] European Association for the Study of the Liver,EASL Clinical Practice Guidelines:The diagnosis and management of patients with primary biliary cholangitis.J Hepatol,2017,67（1）:145-172.
[3] Jungst C,Berg T,Cheng J,et al. Intrahepatic cholestasis in common chronic liver Diseases. Eur J Clin Invest,2013,43（10）:1069-1083.
[4] Jansen PL,Ghallab A,Vartak N,et al. The ascending pathophysiology of cholestatic liver disease. Hepatology,2017,65（2）:722-738.
[5] Nakazawa T,Notohara K,Tazuma S,et al. The 2016 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol,2017,52（7）:838-844.
[6] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51（2）:237-267.
[7] Chalasani NP,Hayashi PH,Bonkovsky HL,et al. ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-
induced liver injury. Am J Gastroenterol,2014,109（7）: 950-966.
[8] Bonkovsky HL,Kleiner DE,Gu J,et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology,2017,65（4）:1267-1277.
[9] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 临床肝胆病杂志,2015,31（11）:1752-1769.
[10] Roberts EA,Schilsky ML.American Association for Study of Liver Diseases（AASLD）. Diagnosis and treatment of Wilson disease:an update. Hepatology,2008,47（6）:2089-111.
[11] Kova JD,Weber MA. Primary biliary cirrhosis and primary sclerosing cholangitis:an Update on MR imaging findings with recent developments. J Gastrointest Liver Dis,2016,25（4）:517-524.
[12] Oertelt S,Rieger R,Selmi C,et al. A sensitive bead assay for antimitochondrial antibodies:Chipping away at AMA-negative primary biliary cirrhosis. Hepatology,2007,45（3）:659-665.
[13] Liu H,Norman GL,Shums Z,et al. PBC screen:an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun,2010,35（4）:436-442.
[14] Kulecka M,Habior A,Paziewska A,et al. Clinical applicability of whole-exome sequencing exemplified by a study in young adults with the advanced cryptogenic cholestatic liver diseases. Gastroenterol Res Pract,2017,2017:4761962.

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Tang Renyi, Hu Qunfeng, Peng Liqing.. Changes of serum lipids, liver function tests and estrogen levels in patients with intrahepatic cholestasis of pregnancy and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(6): 860-863.
[4]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[5]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[6]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[7]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[8]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[9]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[10]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[11]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[12]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[13]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[14]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[15]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.

Diagnosis of patients with unknown cause cholestasis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments